EU green lights AZ, MSD’s rare disease therapy Koselugo
Drug approved to treat children with neurofibromatosis type 1 and plexiform neurofibromas
Read More
Tag: Koselugo
AZ, MSD’s Koselugo bags US approval
The drug is the first in the world to be approved to treat this rare and debilitating genetic condition
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
